Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Change of control calculus

The fate of Biogen Idec Inc.'s two partnered drugs - Tysabri natalizumab and Rituxan rituximab - took center stage last week following BIIB's announcement the prior week that it is considering being acquired and has received interest from several parties, including financier Carl Icahn.

BIIB (Cambridge, Mass.) opened on Monday at $83.35, up $13.92 (20%) from the previous Friday, then cooled to close the week off $3.13 to $80.22.

On Monday, Elan Corp. plc (ELN, Dublin, Ireland) entered the fray, saying it had hired Lehman Brothers to help weigh its options for buying, selling or retaining its 50% interest in U.S. sales of multiple sclerosis treatment Tysabri. It also suggested it might want

Read the full 1127 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE